Treatment success as defined by the authors · people with inflammatory bowel disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment withdrawal for any reason Duration of treatment (range): 12 (3 months) to 36 weeks · heavy menstrual bleeding
LNG‐IUS probably leads to lower withdrawal from treatment for any reason compared with any other medical treatment (moderate certainty).
1 finding from 1 review
Treatment failure · heavy menstrual bleeding
LNG‐IUS probably leads to lower treatment failure compared with any other medical treatment (moderate certainty).
1 finding from 1 review
Intervention not reported
Child medical symptoms, post‐treatment Higher scores indicate greater medical symptoms · parents of children with chronic illness
1 finding from 1 review
Intervention not reported
Child medical symptoms, post‐treatment Higher scores indicate greater medical symptoms · parents of children with chronic illness
1 finding from 1 review
Self‐reported pain (dysmenorrhoea) at the end of treatment (continuous data): dysmenorrhoea at 6 months' · women with endometriosis
2 findings from 1 review
Intervention not reported
Changes of fatigue scores from baseline to after treatment (assessed by energy/fatigue scale from the Medical Outcomes Study) · people with stroke not necessarily having fatigue
1 finding from 1 review
Change in quality of life · treatment for asthma in adults and children with asthma and GORD
1 finding from 1 review
Healthcare utilisation ‐ not measured · treatment for asthma in adults and children with asthma and GORD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Short‐term visual acuity between 20/20 and 20/40 ≤ 2 weeks after treatment; oral corticosteroids · people with traumatic hyphema
Systemic or topical corticosteroids showed no clear difference in short‐term visual acuity between 20/20 and 20/40 ≤ 2 weeks after… compared with placebo or control treatment (low certainty).
1 finding from 1 review
Final visual acuity between 20/20 and 20/40 at end of treatment; oral corticosteroids · people with traumatic hyphema
Systemic or topical corticosteroids showed no clear difference in final visual acuity between 20/20 and 20/40 at end of treatment;… compared with placebo or control treatment (low certainty).
1 finding from 1 review
Short‐term visual acuity between 20/20 and 20/40 ≤ 2 weeks after treatment; topical corticosteroids · people with traumatic hyphema
It is very uncertain whether systemic or topical corticosteroids changes short‐term visual acuity between 20/20 and 20/40 ≤ 2 weeks after… compared with placebo or control treatment (very low certainty).
1 finding from 1 review
Final visual acuity between 20/20 and 20/25 at end of treatment; topical corticosteroids · people with traumatic hyphema
Systemic or topical corticosteroids showed no clear difference in final visual acuity between 20/20 and 20/25 at end of treatment;… compared with placebo or control treatment (low certainty).
1 finding from 1 review
Any severe adverse event during maintenance treatment · people with Crohn's disease who responded to CZP remission‐induction treatment
Certolizumab pegol showed no clear difference in serious adverse events during remission maintenance treatment(1 RCT,… compared with placebo (low certainty).
1 finding from 1 review
RR 0.84 [0.4, 1.78]
Studies not reported
Low
Nausea severity · adults and children having any type of surgical procedure under general anaesthesia, regional anaesthesia or sedation, as hospital…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severity of somatic symptoms at end of treatment · people with somatoform disorders and medically unexplained physical symptoms
1 finding from 1 review
Treatment response at end of treatment · people with somatoform disorders and medically unexplained physical symptoms
1 finding from 1 review
Quality of life at post‐treatment Indexed by self‐report measures of quality of life or functional disability · people with somatoform disorders and medically unexplained physical symptoms
1 finding from 1 review
Healthcare use · people with somatoform disorders and medically unexplained physical symptoms
1 finding from 1 review
Secondary outcome: acceptability of treatment · people with somatoform disorders and medically unexplained physical symptoms
Psychological therapy probably leads to lower acceptability 1 ‐ proportion of participants withdrawing during… compared with usual care or waiting list (moderate certainty).
1 finding from 1 review